SIRT7 Antibody [J3K9]

Catalog No.: F4019

Application: Reactivity: Mouse, Rat, Human

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:30 IHC1:100

Application
WB, IP, IHC

Source
Rabbit Monoclonal Antibody

Reactivity
Mouse, Rat, Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
44 kDa 45 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
SIRT7 Antibody [J3K9] detects endogenous levels of total SIRT7 protein.

Clone
J3K9

Synonym(s)
SIR2L7; SIRT7; NAD-dependent protein deacetylase sirtuin-7; NAD-dependent protein deacylase sirtuin-7; Regulatory protein SIR2 homolog 7; SIR2-like protein 7

Background
SIRT7 is an NAD±dependent deacetylase and Class III HDAC from the conserved sirtuin family SIRT1-7, primarily found in the nucleolus and highly expressed in hematopoietic cells such as myeloid progenitors. SIRT7 is essential for rRNA processing, chromatin silencing, and cellular transformation. It includes a unique N-terminal three-helical domain α1-α3 with arginines R30, R37, R64, R68, and R74 that mediate nucleosome and DNA engagement across the acidic patch and gyres, a flexible linker or hinge helix α2, and a catalytic core featuring DNA-binding loops such as H217, R218, K272-276, R289, and R290. F239 secures H3K36 in the active site, conferring deacylation specificity over H3K18. SIRT7 is recruited by Elk-4 to promoters, where it deacetylates H3K18 to repress transcription, maintains ribosomal biogenesis via RNA polymerase I, and facilitates DNA repair by deacetylating ATM for dephosphorylation. It shifts between tightly gripping DNA when targeting H3K36 and a relaxed, bent linker conformation when targeting H3K18. Overexpression of SIRT7 leads to global reduction of H3K18 acetylation, driving anchorage-independent growth, low-serum survival, cell-cycle entry, escape from contact inhibition, and tumorigenesis in xenograft models, while knockout impairs these transformed phenotypes. In cancer, SIRT7 amplification in prostate, lung, kidney, and pancreas correlates with poor prognosis through H3K18 hypoacetylation, and SIRT7 also promotes leukemia and lymphoma via 17q25 alterations and supports E1A-induced transformation.

Background

SIRT7 is an NAD±dependent deacetylase and Class III HDAC from the conserved sirtuin family SIRT1-7, primarily found in the nucleolus and highly expressed in hematopoietic cells such as myeloid progenitors. SIRT7 is essential for rRNA processing, chromatin silencing, and cellular transformation. It includes a unique N-terminal three-helical domain α1-α3 with arginines R30, R37, R64, R68, and R74 that mediate nucleosome and DNA engagement across the acidic patch and gyres, a flexible linker or hinge helix α2, and a catalytic core featuring DNA-binding loops such as H217, R218, K272-276, R289, and R290. F239 secures H3K36 in the active site, conferring deacylation specificity over H3K18. SIRT7 is recruited by Elk-4 to promoters, where it deacetylates H3K18 to repress transcription, maintains ribosomal biogenesis via RNA polymerase I, and facilitates DNA repair by deacetylating ATM for dephosphorylation. It shifts between tightly gripping DNA when targeting H3K36 and a relaxed, bent linker conformation when targeting H3K18. Overexpression of SIRT7 leads to global reduction of H3K18 acetylation, driving anchorage-independent growth, low-serum survival, cell-cycle entry, escape from contact inhibition, and tumorigenesis in xenograft models, while knockout impairs these transformed phenotypes. In cancer, SIRT7 amplification in prostate, lung, kidney, and pancreas correlates with poor prognosis through H3K18 hypoacetylation, and SIRT7 also promotes leukemia and lymphoma via 17q25 alterations and supports E1A-induced transformation.

References
[1] Moreno-Yruela C, et al. Nat Commun. 2025 Feb 4;16(1):1328. [2] Tang M, et al. Open Biol. 2021 Jun;11(6):210047.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%